15 years’ experience in temperature controlled packaging and logistics.
Serving both the clinical and commercial healthcare supply chain
Working for global organisations and managing sales, marketing, strategy, and global operations.
I’ve worked with medium sized high growth companies coordinating global customer operations as part of acquisitions.
Peli Bio – worked with commercial pharma on vaccine distribution, insulin projects and developed dedicated customer sites. Also, on major global roll out of new packaging solutions for clinical supplies as part of a project team when the customer was developing new dedicated temperature controlled facilities.
Cryopdp – central lab logistics, CROs for biological samples return to lab using dry ice and controlled ambient.
Diversified into new sectors of clinical supplies and Early Access Programs shipping high value temp sensitive products for compassionate use where time to patient is critical.
All of the above means that I have a strong understanding of import and export requirements for non-commercial products
Edo Madussi is the Managing Director, of Euromed Pharma US and Business Unit head of the Clinical Trial Division at the Petrone Group.
His business experience combined with his academic background and four spoken languages – English, German, French, and Italian – brought him to develop an extensive network within the global clinical supply chain space. He is currently developing one of the latest ventures of the Petrone Group: a US-based integrated platform to support Clinical Trial Sponsors and other industry players around the world with a wide range of services in the R&D space.
Dr. Graham Wood is a leader in the conduct and design of clinical pharmacology studies having held senior executive roles in a number of the top clinical research sites in the world.
In total, he has over 22 years of experience and has been involved with more than 200 first-in-human studies as well as over 2,000 studies across all areas of clinical pharmacology.
After finishing his PhD in Neurology and Neurosurgery, Graham worked at MDS Pharma Services, Cetero Research, Manna Research and Altasciences as well as spending two years working at biotechnology companies.
Johanna Morand is the Associate Director, Site Contracts, at Premier Research, responsible for EMEA, LATAM, and APAC, along with the Benelux Country Lead. She has 12 years of experience negotiating contracts for clinical trials (previously with Genzyme, a Sanofi Company, Parexel, and Cmed). Ms. Morand leads an international team of Contract Leads and Contract Specialists. Her aim remains to balance timely execution while managing legal, financial, and operational risks. Ms. Morand holds an LLM in European Law from Leiden University and an LLM in Law and Economics from Utrecht University where she wrote a thesis on European Orphan Medicinal Product Regulations.
Dr. Mahillo has 28+ years of experience in the clinical research arena, 25 of them in oncology global trials. Her areas of expertise are inmuno-oncology, including cancer vaccines, advanced therapies, genetically modified organisms and other immuno therapies. She has an in-depth knowledge on oncology networks and advocacy groups, with which she cooperates since 1999. Dr. Mahillo is a professor/magister in several Master programs administered at different Universities (Universidad Alcalá de Henares, Universidad CEU San Pablo, CESIF). She has authored of 3 books, 20 scientific articles, and 24 contributions to scientific congresses. Dr. Mahillo was awarded the first prize of the Spanish Society of Medical Oncology (SEOM) in 2015 for her project “Y Seguiré” (will keep on moving), for the promotion of clinical research. Dr. Mahillo obtained her PhD with a research on the role of multicatalytic proteinase (proteasome) as an oncology intracellular target, research line that ended up with the development of bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma patients.
After qualifying as a barrister, Ian re-trained as a chartered accountant with Deloitte, working with brokers and insurers in the UK and international markets. Over 14 years, he helped build a regulatory consulting practice of 50 professionals, led the client money and regulatory diligence offering for Deloitte, conducted skilled persons investigations and supported insurance clients on all aspects of UK financial regulation. In 2020, Ian joined Aston Lark Group as Chief Risk Officer, working alongside Peter Blanc to transform the governance, risk and compliance arrangements and supporting the business through more than 30 acquisitions. Ian is responsible for the ESG strategy for the Aston Lark Group, expanding its remit as the group has grown by adding new initiatives and networks and increasing staff engagement.
